Molecular impact of bone morphogenetic protein 7, on lung cancer cells and its clinical significance

International Journal of Molecular Medicine

Volumn 29, Issue 6, 2012, Pages 1016-1024

  Liu, Yinan ^a,b   Chen, Jinfeng ^a,b   Yang, Yue ^a   Zhang, Lijian ^a   Jiang, Wen G ^b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Apoptosis; Bone metastasis; Bone morphogenetic protein 7; Cell migration; Lung cancer; Tet inducible expression

Indexed keywords

ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; OSTEOGENIC PROTEIN 1; BMP7 PROTEIN, HUMAN; SMALL INTERFERING RNA; TETRACYCLINE;

APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER PATIENT; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR MODEL; CANCER INVASION; COHORT ANALYSIS; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; STAINING; TIME; TUMOR CELL LINE; WOUND HEALING;

BONE MORPHOGENETIC PROTEIN 7; CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PROGNOSIS; RNA, SMALL INTERFERING; STAINING AND LABELING; TETRACYCLINE; TIME FACTORS; TUMOR STEM CELL ASSAY; WOUND HEALING;

EID: 84860505713     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.948     Document Type: Article

References (29)

1. Leung-Hagesteijn C, Hu MC, Mahendra AS, Hartwig S, et al: Integrin-linked kinase mediates bone morphogenetic protein 7-dependent renal epithelial cell morphogenesis. Mol Cell Biol 25: 3648-3657, 2005. (Pubitemid 40559571)
2. Morrissey C, Brown LG, Pitts EM, et al: Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumour microenvironment. Neoplasia 12: 192-205, 2010.
3. Cassar L, Nicholls C, Pinto AR, et al: Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3. FASEB J 23: 1880-1892, 2009.
4. Aoki M, Ishigami S, Uenosono Y, et al: Expression of BMP7 in human gastric cancer and its clinical significance. Br J Cancer 104: 714-718, 2011.
5. Chen JF, Ye L, Xie F, et al: Expression of bone morphorgenetic protein-7 in lung cancer and its biological impact on lung cancer cells. Anticancer Res 30: 3-10, 2010.
6. Rothhammer T, Wild PJ, Meyer S, et al: Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark 3: 111-117, 2007. (Pubitemid 47103812)
7. Cassar L, Li H, Pinto AR, et al: Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumour growth. Cancer Res 68: 9157-9166, 2008.
8. Hsu MY, Rovinsky S, Lai CY, et al: Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation. Lab Invest 88: 842-855, 2008.
9. Takahashi M, Otsuka F, Miyoshi T, et al: Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol 199: 445-455, 2008.
10. Notting I, Buijs J, Mintardjo R, et al: Bone morphogenetic protein 7 inhibits tumor growth of human uveal melanoma in vivo. Invest Ophthalmol Vis Sci 48: 4882-4889, 2007. (Pubitemid 351260892)
11. Yan W and Chen X: Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells. Cancer Res 67: 9117-9124, 2007. (Pubitemid 47535897)
12. Alarmo EL, Rauta J, Kauraniemi P, et al: Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 45: 411-419, 2006. (Pubitemid 43346773)
13. Yang S, Lim M, Pham LK, et al: Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. Cancer Res 66: 4285-4290, 2006.
14. Langenfeld EM, Bojnowski J, Perone J, et al: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 80: 1028-1032, 2005. (Pubitemid 41196808)
15. Alarmo EL, Korhonen T, Kuukasjarvi T, et al: Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol 19: 308-314, 2007.
16. Bujis JT, Henriquez NV, van Overveld PG, et al: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67: 8742-8751, 2007. (Pubitemid 47437450)
17. Alarmo EL, Parssinen J, Ketolainen JM, et al: BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett 275: 35-43, 2009.
18. Buijs JT, Rentsch CA, van der Horst G, et al: BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171: 1047-1057, 2007. (Pubitemid 47441001)
19. Yang S, Zhong C, Frenkel B, et al: Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65: 5769-5777, 2005 (Pubitemid 40911180)
20. Ye L, Lewis JM, Sanders AJ, et al: HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urol Oncol 26: 190-197, 2008. (Pubitemid 351288565)
21. Ye L, Lewis-Russell JM, Kynaston H, et al: Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 178: 1086-1091, 2007. (Pubitemid 47211048)
22. Grijelmo C, Rodrigue C, Svrcek M, et al: Proinvasive activity of BMP7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal 19: 1722-1732, 2007. (Pubitemid 46935428)
23. Na YR, Seok SH, Kim DJ, et al: Bone morphogenetic protein 7 induces mesenchymal-to-epithelial transition in melanoma cells, leading to inhibition of metastasis. Cancer Sci 100: 2218-2225, 2009.
24. Motovama K, Tanaka F, Kosaka Y, et al: Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 15: 1530-1507, 2008.
25. Lim MY, Zhong C, Yang SX, et al: Runx2 regulates survivin expression in prostate cancer cells. Lab Invest 90: 222-233, 2010.
26. Bujis JT, Henriguez NV, van Overveld PG, et al: TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis 24: 609-617, 2007.
27. Basic-Jukic JN, Hudolin T, Radic-Antolic M, et al: Bone morphogenetic protein-7 expression is downregulated in human clear cell renal carcinoma. J Nephrol 24: 91-97, 2011.
28. Fournier PG and Guise TA: BMP7: a new bone metastases prevention? Am J Pathol 171: 739-743, 2007. (Pubitemid 47440973)
29. Masuda H, Fukabori Y, Nakano K, et al: Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54: 268-274, 2003. (Pubitemid 36228163)